For EBV-driven nasopharyngeal carcinoma, EV-packaged viral miRNAs (miR-BART13-3p) and host proteins (CYPA) achieve superior sensitivity over conventional EBV-DNA testing, particularly in seronegative cases. The gene discussed is PPIA; the disease is nasopharyngeal carcinoma.